These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23565515)

  • 1. [Therapy of AL-amyloidosis in 2012, role of new drugs--editorial].
    Tóthová E
    Vnitr Lek; 2013 Jan; 59(1):13-5. PubMed ID: 23565515
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is the approach to therapy of AL-amyloidosis changing--editorial].
    Elbl L
    Vnitr Lek; 2013 Feb; 59(2):96-8. PubMed ID: 23599969
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Charliński G; Wiater E; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis.
    Dubrey SW; Patel K; Lachmann H; Sugai T; Cook T; Hill P
    Br J Hosp Med (Lond); 2016 Mar; 77(3):188-9. PubMed ID: 26961452
    [No Abstract]   [Full Text] [Related]  

  • 6. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone.
    Kikukawa Y; Hata H; Ueda M; Yamashita T; Nasu S; Ide K; Ueno S; Ando Y; Mitsuya H; Okuno Y
    Intern Med; 2016; 55(18):2707-12. PubMed ID: 27629972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis.
    Perfetto F; Casagrande S; Barilaro A; Di Gioia M; Santi R; Allinovi M; Romoli S; Boschi A; Desideri I; Taborchi G; Ungar A; Cappelli F
    Intern Emerg Med; 2021 Oct; 16(7):1927-1933. PubMed ID: 32926355
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
    Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
    Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.
    Shaulov A; Ganzel C; Benyamini N; Barshay Y; Goldschmidt N; Lavie D; Libster D; Gural A; Avni B; Gatt ME
    Am J Hematol; 2017 Feb; 92(2):131-135. PubMed ID: 27804150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
    Huang X; Wang Q; Chen W; Ren G; Liu Z
    Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.
    Meshitsuka S; Shingaki S; Hotta M; Goto M; Kobayashi M; Ukawa Y; Sagesaka YM; Wada Y; Nojima M; Suzuki K
    Int J Hematol; 2017 Mar; 105(3):295-308. PubMed ID: 27815860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long standing polyneuropathy as a form of presentation of primary systemic amyloidosis.
    Jiménez Caballero PE
    Neurologia; 2012 Sep; 27(7):447-8. PubMed ID: 22217524
    [No Abstract]   [Full Text] [Related]  

  • 17. [Three patients with primary AL amyloidosis treated by high-dose melphalan with autologous peripheral blood stem cell transplantation].
    Mukai S; Kanashima H; Ogawa Y; Nakao T; Teshima H; Yamane T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):625-7. PubMed ID: 22504689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of primary systemic amyloidosis.
    Mirfeizi Z; Hatef MR; Hashemzadeh K; Hashemzadeh S; Tayebi N
    Int J Rheum Dis; 2012 Oct; 15(5):e134-5. PubMed ID: 23083051
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.